In short
Clinical trials are studying GSKVX000000034792 in healthy younger and older adults to find and confirm a dose and to assess safety, reactogenicity, and immune response. The trial also compares immune responses after vaccination. These studies help researchers understand how the vaccine performs in prevention of influenza infection.
Key points
- GSKVX000000034792 was studied in a Phase 1/2 trial in healthy younger and older adults. The main goal was to find and confirm the dose and to assess safety, reactogenicity, and immune response. The study focused on prevention of influenza infection. Researchers measured local and systemic reactions, adverse events, serious adverse events, and antibody responses. The trial was completed and enrolled 1272 participants.
Trial overview
The clinical trial for GSKVX000000034792 was a vaccine study in healthy younger and older adults. It was designed to find and confirm the dose and to assess safety, reactogenicity, and immune response.
The study looked at prevention of influenza infection, which means it focused on helping the body build protection against the flu before infection happens.
Who was studied
The trial included healthy volunteers, split into younger and older adults. This matters because immune responses can be different in different age groups, so the study could compare how well the vaccine worked across ages.
The study was not focused on people who already had influenza. It was aimed at prevention in people who were healthy at the time of vaccination.
Study design and phase
This was an interventional study, which means researchers gave the study vaccine and then observed what happened. The phase was Phase 1/2, an early stage of clinical testing that combines safety and dose finding with early immune response testing.
The trial was completed and enrolled 1272 participants. The study also included comparison vaccines, which helped researchers compare the immune response and safety profile across different study groups.
What was measured
The main outcomes focused on safety and reactogenicity. The study measured local events at the injection site and systemic events in the body from Day 1 to Day 7.
It also measured unsolicited adverse events from Day 1 to Day 28, serious adverse events from Day 1 to Day 183, adverse events of special interest from Day 1 to Day 183, and medically attended events from Day 1 to Day 183. In Phase 1 only, the study checked for changes in laboratory values from normal to clinically significant abnormal results after vaccination.
For immune response, the trial measured geometric mean titer (GMT), geometric mean increase, seroconversion rate, and whether antibody levels reached a set cut-off value for two antigens at Day 29. These measures help show whether the vaccine triggered the body to make antibodies against the flu antigens.
What the trial was trying to learn
The brief summary shows two main goals: to evaluate the safety and reactogenicity profile of the investigational study intervention, and to evaluate the humoral immune response. Humoral immune response means the part of the immune system that makes antibodies in the blood.
Because the study was in healthy adults, the results are most useful for understanding how the vaccine performs in people without current influenza illness. The trial data do not provide a treatment claim for sick patients; they describe a prevention-focused vaccine study.
Key terms explained
Solicited events are symptoms or reactions that researchers ask participants about on purpose, usually soon after vaccination. Unsolicited adverse events are any other unwanted medical problems that participants report during the study period.
Serious adverse events are medical problems that are more severe, such as those that are life-threatening or need hospital care. Medically attended events are problems that lead a participant to seek medical care.
Antigen means a part of the vaccine or virus that the immune system recognizes and responds to. Seroconversion means a change in blood test results that shows a new antibody response after vaccination.